Peyronie Disease: Diagnosis, Acute vs Chronic Phase, and Management Options
Executive Summary
Peyronie disease is an acquired fibrotic disorder of the tunica albuginea of the penis that produces palpable plaque, painful erections, and abnormal penile curvature. The cumulative prevalence in adult men approaches 9 percent, with peak incidence in the sixth decade, though the true prevalence is likely higher because the disease is widely under-reported. Clinical management depends fundamentally on phase: the acute (inflammatory) phase lasting 6 to 18 months features pain, evolving curvature, and a tender plaque, and is treated with conservative measures aimed at limiting progression — oral pentoxifylline, intralesional verapamil, mechanical traction, and supportive counseling. The chronic (stable) phase begins when curvature stops progressing and pain resolves, opening eligibility for definitive interventions including intralesional collagenase clostridium histolyticum (Xiaflex) for moderate curvature 30 to 90 degrees, and surgical correction (plication, plaque incision with grafting, or penile prosthesis) for greater than 60 degree curvature, complex deformities, or coexisting refractory erectile dysfunction. The cardinal mistake is offering surgery or collagenase during the acute phase before disease has stabilized.
Pathophysiology and Risk Factors
Peyronie disease is a localized fibroproliferative disorder of the tunica albuginea — the dense connective tissue layer surrounding the corpora cavernosa. The pathologic process is initiated by microtrauma during intercourse or sleep that produces small tears in the tunica, particularly at the septal attachments where the dorsal and ventral tunica converge. In susceptible individuals, the healing response is dysregulated: instead of producing organized collagen, fibroblasts deposit disorganized type I and type III collagen and elastic fiber bundles that contract over time, producing the characteristic plaque. Calcification develops in advanced disease as the plaque becomes metabolically inactive.
The molecular cascade involves TGF-β1 (transforming growth factor beta), plasminogen activator inhibitor-1 (PAI-1), and reactive oxygen species. TGF-β1 drives myofibroblast differentiation and collagen production; PAI-1 prevents fibrinolysis and allows persistence of the fibrin matrix; reactive oxygen species perpetuate inflammation. Genetic susceptibility appears to involve multiple loci, with strong overlap with other fibrotic disorders.
Recognized associations strengthen the suspicion for Peyronie:
- Dupuytren contracture — fibrotic palmar fascia disorder; co-occurs in 9 to 39 percent of Peyronie patients and shares the same fibroblast biology
- Ledderhose disease (plantar fibromatosis) — analogous foot fibrosis, also shares biology
- Diabetes mellitus — 2 to 4× increased risk; impairs healing of microtrauma
- Hypogonadism (low testosterone) — associated but causal relationship debated
- Cardiovascular disease and erectile dysfunction — coexist in approximately 50 percent of Peyronie patients, consistent with shared microvascular pathology
- Tobacco use — modest increased risk
- Family history — first-degree relatives have 4-fold increased risk
- Connective tissue disorders — Marfan, Ehlers-Danlos, scleroderma rare associations
The condition is not infectious, not transmissible, and not caused by sexual practices in any meaningful way. Patients commonly present with significant anxiety about etiology — clear early reassurance that the disease is a healing response to small tears, not a punishment for behavior, helps establish the therapeutic relationship.
Acute vs Chronic Phase Staging
The phase distinction is the most important clinical decision in Peyronie management. It dictates which treatments are appropriate, sets patient expectations about timeline, and defines the natural history.
| Feature | Acute (inflammatory) phase | Chronic (stable) phase |
|---|---|---|
| Duration | 6–18 months from onset | Begins ≥12 months from onset; persistent |
| Pain with erection | Present in ~50% | Resolved in >90% |
| Curvature | Evolving, may worsen month to month | Stable on serial measurements |
| Plaque characteristics | Tender, palpable, soft | Firm, often calcified, non-tender |
| Therapy | Conservative: traction, oral, intralesional verapamil | Collagenase or surgery |
| Surgical eligibility | Contraindicated — curvature will change | Eligible if stable ≥6–12 months |
| Collagenase eligibility | Contraindicated | Eligible if 30–90° curvature, palpable plaque |
The transition from acute to chronic is confirmed by two consecutive office visits 3 months apart with stable curvature measurements and resolved pain. Photographs of the erect penis at each visit provide objective documentation. Patient self-reports of stability are supportive but not sufficient — many patients perceive their curvature as stable after subjective adjustment when serial measurement reveals slow progression.
Why the phase matters: surgical correction performed during the acute phase will need revision when the disease continues to progress, and intralesional collagenase has not been validated in active disease. Equally important, expensive interventions during the acute phase may produce changes that would have occurred with conservative management alone — there is no good way to determine whether observed improvement was treatment effect or natural history.
Diagnosis and Quantification
Peyronie diagnosis is clinical. Physical exam in the flaccid state identifies the plaque as a discrete area of induration along the dorsal, lateral, or (less commonly) ventral aspect of the penile shaft. The dorsal location is most common (~60 percent), reflecting the higher mechanical stress on the dorsal septum during intercourse. Plaques may be solitary or multiple; multiple plaques predict more complex deformity (hourglass, hinge effect).
Curvature Assessment
Quantitative curvature measurement is essential and requires the erect penis. Two approaches:
- Patient-provided photographs: the patient photographs the erect penis from three angles (lateral, dorsal, and any prominent angulation) on a flat surface with a measuring tape for scale. Privacy is maintained; goniometric measurement is performed in clinic.
- In-office induced erection: intracavernosal injection of alprostadil 5 to 20 mcg or a trimix combination produces a controlled erection for objective measurement and ultrasound. This is the gold standard but requires a dedicated visit.
Curvature is reported in degrees from the long axis (e.g., "45 degrees dorsal curvature"). Severity grading: mild (<30°), moderate (30 to 60°), severe (>60°). Curvature greater than 60 degrees often prevents intercourse and is a strong indication for definitive intervention.
Penile Duplex Ultrasound
Doppler ultrasound after intracavernosal injection serves multiple purposes: visualizes plaque thickness and calcification, assesses cavernosal artery peak systolic velocity (PSV) to identify vascular contributions to erectile dysfunction, and identifies venous leak. PSV less than 25 cm/s indicates arterial insufficiency; end-diastolic velocity (EDV) greater than 5 cm/s indicates venous leak. These findings substantially affect treatment selection — combined Peyronie disease and erectile dysfunction may favor penile prosthesis over plication or grafting.
Erectile Function Quantification
The International Index of Erectile Function (IIEF) short form (5 items) provides a baseline measure of erectile function. Many Peyronie patients have coexistent erectile dysfunction that affects treatment selection. The Peyronie Disease Questionnaire (PDQ) is a validated 15-item instrument assessing pain, symptom bother, and psychological impact — useful as a baseline and outcome measure.
Acute Phase Management
The aim of acute-phase therapy is to limit progression of curvature and provide pain relief. No therapy reliably reverses established curvature in the acute phase. Several approaches have evidence-based support and are typically used in combination.
Mechanical Traction Therapy
Penile traction devices apply continuous gentle stretch to the corpora cavernosa for 2 to 8 hours per day. The mechanism is mechanotransduction-driven remodeling of the fibrotic plaque. Multiple randomized trials have shown small reductions in curvature (5 to 15 degrees) and improvement in penile length when used for at least 6 months. Traction is most effective during the acute phase but useful in chronic phase also. Adherence is the limiting factor — daily multi-hour wear is a substantial commitment. Newer devices (RestoreX) have reduced daily wear time to 30 to 90 minutes per day, improving adherence with similar outcomes.
Oral Therapy
| Drug | Dose | Evidence | Role |
|---|---|---|---|
| Pentoxifylline | 400 mg PO TID × 6 months | Small RCTs show reduced calcification, modest curvature improvement | First-line acute phase oral; well-tolerated |
| Vitamin E | 400 IU PO BID | Mixed; recent meta-analyses negative | Often used for low-cost option but evidence weak |
| Colchicine | 0.6 mg PO BID | Mixed evidence; GI intolerance limits use | Adjunct; rarely first-line |
| L-arginine, L-carnitine | Variable | Limited evidence | Often combined with pentoxifylline |
| PDE5 inhibitors (tadalafil 5 mg daily) | Tadalafil 5 mg PO daily | Animal models suggest antifibrotic effect; clinical data emerging | Especially useful when ED coexists |
Intralesional Verapamil
Verapamil 10 mg in 10 mL diluent injected into the plaque every 2 weeks for 12 sessions (6 months) has been used for decades. The evidence is modest but supportive — meta-analyses suggest curvature reduction of approximately 10 degrees. Verapamil is inexpensive and has minimal systemic effects. Use is largely limited to acute phase or as a bridge while waiting for chronic-phase eligibility for collagenase.
Intralesional Interferon
Intralesional interferon alpha-2b 5 million units in 10 mL saline every 2 weeks × 6 doses reduces inflammation and fibrosis. RCT evidence shows modest curvature improvement. Cost and flu-like systemic side effects (fever, myalgias) limit use. Generally reserved for patients who cannot use or have failed verapamil.
What to Avoid in the Acute Phase
- Surgical reconstruction — disease will continue to progress
- Intralesional collagenase — not studied or approved in acute phase
- Aggressive injection regimens — may worsen inflammation
- Vacuum erection devices alone — limited evidence; can cause additional microtrauma if misused
Clinical Pearl
Use the acute phase wisely. Even though no acute-phase therapy is dramatically effective, the time spent in conservative therapy builds the doctor-patient relationship, allows the patient to develop realistic expectations, and confirms phase transition through serial measurement. Counsel the patient that the goal is to limit progression — not to reverse curvature — until the disease stabilizes.
Common Pitfall
Offering surgery during active disease because the patient is highly symptomatic. The surgical result will need revision when the disease continues to progress. The cardinal rule: stable curvature for at least 6 to 12 months before any surgical intervention. Document stability with serial photographs and measurements.
Chronic Phase: Collagenase and Surgery
Intralesional Collagenase Clostridium Histolyticum (Xiaflex)
Collagenase clostridium histolyticum is the only FDA-approved drug therapy for Peyronie disease. The drug enzymatically cleaves type I and type III collagen, the dominant components of the Peyronie plaque. The IMPRESS phase 3 trials (Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) demonstrated curvature improvement of approximately 17 degrees (~34 percent reduction from baseline) with collagenase versus 9 degrees with placebo over 4 treatment cycles.
Eligibility criteria: stable disease, palpable plaque, curvature 30 to 90 degrees (excluded if >90 or hourglass deformity), and intact erectile function (or responsive to PDE5 inhibitors). Treatment protocol:
- One cycle = 2 injections into the plaque separated by 1 to 3 days, followed by penile modeling 1 to 3 days after the second injection
- Total course = 4 cycles over 6 to 12 months (cycles separated by ~6 weeks)
- Penile modeling = manual stretching by the clinician (and self-modeling by the patient) to fracture residual plaque after enzymatic disruption
Adverse events include penile bruising and swelling (very common, expected), localized hematoma (5 to 10 percent), pain at injection site, and the most serious — corporal rupture (penile fracture), which occurs in approximately 1 percent of cycles. Patients must abstain from intercourse and self-modeling during specific windows around injection. Cost is substantial (~$30,000 to $50,000 USD for a full course), and insurance coverage is variable.
Surgical Reconstruction
Surgery remains the most effective definitive treatment for Peyronie disease and is the standard for severe curvature, complex deformity, and disease that fails or is ineligible for collagenase. Three procedures address the three major presentations:
| Procedure | Best candidate | Mechanism | Trade-offs |
|---|---|---|---|
| Plication (Nesbit, Yachia, Heineke-Mikulicz) | Curvature ≤60°, intact erectile function, adequate length | Shortens convex side to match concave side | Penile shortening 0.5–1.5 cm; high straightening rate; preserves sensation |
| Plaque incision/excision with grafting | Curvature >60°, hourglass deformity, intact erectile function | Removes/incises plaque, fills defect with graft (autologous, dermal, bovine pericardium) | Length-preserving; risk of postoperative ED 10–20%; longer recovery |
| Inflatable penile prosthesis (IPP) ± modeling | Coexisting refractory ED with Peyronie | Replaces erectile mechanism; cylinders straighten curvature with manual modeling at implantation | Definitive solution for combined ED+Peyronie; requires lifelong device; infection risk 1–3% |
Patient selection considerations: a man with adequate erectile function, mild-moderate curvature, and acceptable preoperative penile length is well served by plication with high satisfaction. A man with severe curvature, hourglass deformity, or substantial preoperative length loss benefits from grafting. A man with combined Peyronie disease and refractory erectile dysfunction is best served by penile prosthesis with intraoperative modeling — this addresses both problems definitively in a single procedure.
Outcomes: plication produces straightening rates greater than 90 percent with high satisfaction. Grafting produces straightening greater than 90 percent but with 10 to 20 percent rate of new or worsened erectile dysfunction. IPP produces excellent satisfaction in patients with combined disease, with greater than 90 percent satisfaction at 1 year.
Erectile Dysfunction Comorbidity, Counseling, and Follow-Up
Coexisting Erectile Dysfunction
Approximately 50 percent of Peyronie patients have coexistent erectile dysfunction. The relationship is bidirectional — Peyronie can produce ED through psychological distress and vascular impingement, and underlying vascular ED contributes to the microtrauma that initiates Peyronie. Evaluation should include IIEF-5 scoring, duplex ultrasound for vascular assessment, and trial of PDE5 inhibitor when erectile complaints are present.
Treatment of coexistent ED is integrated with Peyronie management:
- Tadalafil 5 mg PO daily — daily PDE5 inhibitor may have antifibrotic benefit and supports erectile function during conservative therapy
- Sildenafil 50–100 mg PO PRN or Tadalafil 10–20 mg PO PRN — on-demand PDE5i for ED
- Vacuum erection devices — supplement erectile function and may have modest stretching benefit
- Penile prosthesis — definitive for refractory ED with concurrent Peyronie correction
Counseling and Psychological Support
Peyronie disease produces significant psychological burden. Depression, anxiety, and relationship distress affect 50 to 75 percent of patients. Open discussion at each visit, validation of the impact, and referral to mental health support when needed are essential components of care. Partner involvement when possible improves adherence and outcomes. Online support groups and patient advocacy organizations (Association of Peyronie’s Disease Advocates) provide community and information.
When to Refer
Follow-Up
Acute phase: every 3 months with photographs and measurements. Chronic phase pre-treatment: every 3 to 6 months until intervention. Post-collagenase: at 6 weeks, 3 months, and 6 months after the last cycle. Post-surgery: at 2 weeks, 6 weeks, 3 months, 6 months, and annually thereafter. Long-term recurrence after successful surgery is uncommon (<10 percent at 5 years), but new plaques in different locations occur in 5 to 10 percent.
Frequently Asked Questions
S7. Practice Insights: Phase Determines Everything in Peyronie Disease
1. Acute vs Chronic Phase Determination
In practice, every Peyronie patient is staged as acute or chronic phase at the initial visit. Acute phase (typically months 1-12 from symptom onset) is characterized by ongoing pain during erection, palpable inflammatory plaque, progressing curvature on serial measurement. Chronic phase (typically >12 months) shows no pain, stable plaque size, and unchanged curvature angle for at least 3 consecutive months. The clinical importance is that surgical or invasive interventions during acute phase risk recurrence in the new position because the disease is still progressing — definitive intervention requires plaque stabilization. The opposite mistake is treating chronic phase with anti-inflammatory therapies that no longer have a target. clinicians document the phase explicitly at every visit and re-stage if symptoms suggest reactivation.
2. Objective Curvature Quantification
In experienced hands, subjective patient report of curvature is unreliable for both initial assessment and follow-up. Experienced clinicians require objective documentation through one of three methods: patient-submitted photographs of erection (with explicit consent and HIPAA-secure transmission, taken from three angles — dorsal, ventral, lateral), in-clinic intracavernosal injection of vasoactive agent (alprostadil 5-10 mcg) with goniometric measurement at full erection, or duplex ultrasound at maximum erection with measurement. Curvature is reported in degrees from baseline (straight). Curvature less than 30 degrees often does not impact sexual function meaningfully; 30-60 degrees significantly impacts function; greater than 60 degrees often prevents penetration. Hourglass or hinge deformity adds functional impact beyond simple angulation.
3. Collagenase (Xiaflex) for Stable 30-90 Degrees
Intralesional collagenase clostridium histolyticum (CCH/Xiaflex) is FDA-approved for adult men with Peyronie disease with palpable plaque and curvature ≥30 degrees, in stable chronic phase. The treatment course is 4 cycles, each consisting of 2 injections 1-3 days apart followed by modeling/stretching exercises. Total of 8 injections over 24 weeks. In experienced hands, response is typically a 30-40% reduction in curvature angle, which translates to clinically meaningful improvement in sexual function in many patients but does not “cure” the disease. Common complications include local penile bruising and pain; rare but serious complications include corporal rupture (~1%, especially with overly vigorous modeling exercises). Patients must avoid sexual activity for 14 days after each injection cycle. clinicians counsel explicitly about the 30-40% improvement expectation to avoid disappointment from unrealistic expectations.
4. Surgery for Severe Stable Disease
Surgical reconstruction is reserved for severe Peyronie disease with disability from curvature, hourglass deformity, or hinge effect, in stable disease for at least 12 months, often after failed CCH. Two main approaches: plication (Nesbit, Yachia, or 16-dot procedures) for curvatures less than 60-70 degrees in patients without preexisting ED, with expected post-surgical length loss of 0.5-1 cm; plaque incision/excision with grafting (Egydio or similar) for severe curvature or hourglass deformity, with higher rate of postoperative ED and potentially longer length loss but better correction for severe disease. Penile prosthesis with simultaneous manual or surgical straightening is the option for patients with significant concurrent ED. clinicians counsel every surgical candidate about realistic outcomes: residual curvature is common, length loss is essentially universal with plication, and ED can occur post-surgically — particularly important for patients with significant pre-operative ED who may need prosthesis from the outset.
Illustrative Scenario: Failed Acute-Phase Surgery Avoided by Phase Discipline
A middle-aged man presented 4 months after onset of penile pain with erections and progressive dorsal curvature now approximately 55 degrees, with active pain on erection and a palpable inflammatory plaque. He had been referred by an outside urologist who was about to schedule plication surgery. He came for second opinion because his wife felt the timing seemed early.
On the evaluation he was clearly in active acute phase — ongoing pain, palpable tender plaque, curvature that had progressed from 30 to 55 degrees over the prior 8 weeks documented by patient photographs. clinicians counseled against immediate surgery and recommended a 12-month observation/stabilization period with pentoxifylline 400 mg TID and conservative management. Over the next 8 months his pain resolved, plaque became less prominent, and curvature stabilized at 48 degrees (some spontaneous improvement). At 12 months he was clearly chronic phase. The treating clinicians then completed 4 cycles of Xiaflex with reduction of curvature to 30 degrees (achievable for satisfactory intercourse without further surgery). At 2-year follow-up he remained stable, sexually functional, and had avoided surgery entirely.
Practice Pattern Refinements vs Standard Approach
- Phase determination at every visit: acute (months 1-12, pain + progression) vs chronic (>12 mo, stable 3+ months). No surgery in acute phase.
- Objective curvature quantification: photo from 3 angles OR in-clinic injection with goniometric measurement OR duplex US. Document in degrees.
- CCH (Xiaflex) 4-cycle protocol for stable curvature 30-90°; counsel about 30-40% expected reduction. Modeling exercises with corporal rupture risk (~1%).
- Surgery for severe stable disease >12 months only: plication if <60-70° without ED; graft if severe/hourglass; prosthesis if concurrent ED. Counsel about realistic length loss and residual curvature.
- Benign Prostatic Hyperplasia: IPSS, Medical Therapy, and Surgical Options
- Phimosis and Paraphimosis: Topical Steroids, Manual Reduction, and Circumcision Indications
- Erectile Dysfunction: Evaluation and Stepwise Treatment
- Microscopic Hematuria: AUA Risk Stratification, Cystoscopy & Imaging Strategy
- Vesicoureteral Reflux: Grading, VCUG/DMSA Imaging, CAP, and Endoscopic vs Surgical Repair
- Urge Urinary Incontinence: Evaluation and Treatment